The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | ASH Highlights in CLL: moving towards fixed-duration treatment, the role of MRD & ALPINE results
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, shares his highlights in chronic lymphocytic leukemia (CLL) from the ASH meeting, discussing the move towards fixed-duration therapy, the impact of measurable residual disease (MRD) on treatment decisions, and the results of the ALPINE study (NCT03734016) which compared zanubrutinib with ibrutinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MSD: Consultancy, Honoraria; Roche: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Lilly/Loxo: Consultancy, Honoraria.
